{
    "clinical_study": {
        "@rank": "6750", 
        "arm_group": {
            "arm_group_label": "Carfilzomib", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive standard fludarabine-based conditioning regimen (fludarabine + busulfan or fludarabine + melphalan), followed by an allogeneic hematopoietic cell transplantation, with the addition of carfilzomib.  Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7."
        }, 
        "brief_summary": {
            "textblock": "The in vestigators are conducting a phase 1/2 study of fludarabine-based allo-HCT with the\n      addition of carfilzomib in patients with hematologic malignancy.  The investigators\n      hypothesize that adding carfilzomib to standard fludarabine-based conditioning regimen for\n      allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant\n      relapse and treatment-related mortality by decreasing severe GVHD, leading to overall\n      improvement in transplant outcomes."
        }, 
        "brief_title": "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies", 
        "condition": [
            "Hematologic Malignancies", 
            "Allogeneic Transplantation", 
            "Carfilzomib", 
            "Relapse", 
            "Graft-Versus-Host Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Graft vs Host Disease", 
                "Recurrence", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Lymphoid or Myeloid malignancy requiring allogeneic hematopoietic cell\n             transplantation\n\n          -  Pathology review by the study institution is required\n\n          -  Prior high-dose chemotherapy and autologous HCT(s) is (are) allowed\n\n          -  Disease status: Stable disease or better at the time of enrollment\n\n          -  Age: >18 and <65 years old at the time of transplant\n\n          -  Life expectancy \u2265 6 months after transplant\n\n          -  A 8/8 or 7/8 HLA-matched donor is available\n\n          -  Karnofsky Performance Status >70% (A measure of quality of life that ranges from 0 to\n             100 where 100 equals perfect health and 0 is death.)\n\n          -  Adequate cardiac [LVEF (Left Ventricular Ejection Fraction) >0.4], pulmonary [FEV1\n             (Forced Expiratory Volume in 1 Second), FVC (Forced Vital Capacity), corrected DLCO\n             (Diffusing Capacity) \u2265 50% predicted], hepatic [DB (Direct Bilirubin) <1.5xULN, AST\n             (Aspartate Aminotransferase) / ALT (Alanine transaminase) \u22643xULN] and renal function\n             [GFR (Glomerular Filtration Rate) \u2265 60 mL/min/1.73 m2]\n\n        Exclusion Criteria:\n\n          -  Progressive disease\n\n          -  Active central nervous system involvement by malignancy\n\n          -  Non compliance to medications or medical instructions\n\n          -  Lack of appropriate caregivers\n\n          -  Life expectancy <6 months\n\n          -  Pregnant or lactating females\n\n          -  Uncontrolled infection requiring active treatment (systemic antibiotics, anti-virals,\n             or anti-fungals) within 14 days\n\n          -  HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity\n\n          -  Active hepatitis A, B or C infection\n\n          -  Unstable angina or myocardial infarction within 6 months prior to randomization, NYHA\n             Class III or IV heart failure, uncontrolled angina, history of severe coronary artery\n             disease, uncontrolled or persistent atrial fibrillation/flutter, history of\n             ventricular fibrillation, ventricular tachycardia/torsade de pointes, sick sinus\n             syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction\n             system abnormalities unless subject has a pacemaker\n\n          -  History of pulmonary hypertension\n\n          -  Uncontrolled hypertension or uncontrolled diabetes mellitus\n\n          -  Non-hematologic malignancy within the past 3 years with the exception of a)\n             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid\n             cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason\n             Grade 6 or less with stable prostate-specific antigen (PSA) levels; or d) cancer\n             considered cured by surgical resection or unlikely to impact survival during the\n             duration of the study, such as localized transitional cell carcinoma of the bladder\n             or benign tumors of the adrenal or pancreas\n\n          -  Known history of allergy to Captisol\u00ae (a cyclodextrin derivative used to solubilize\n             carfilzomib)\n\n          -  Contraindication to any of the required concomitant drugs or supportive treatments,\n             including hypersensitivity to all available anti-microbial drugs or intolerance to IV\n             hydration due to pre-existing pulmonary or cardiac impairment\n\n          -  Subjects with pleural effusion requiring thoracentesis or ascites requiring\n             paracentesis within 14 days prior to admission\n\n          -  Uncontrolled psychiatric condition\n\n          -  Any other clinically significant medical or psychiatric disease or condition that, in\n             the Investigator's opinion, may interfere with protocol adherence or a subject's\n             ability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145403", 
            "org_study_id": "UMCC 2014.010", 
            "secondary_id": "HUM00084170"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.\nDose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels.", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": "Kyprolis\u00ae"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Fludarabine will be administered at 40 mg/m2/day IV x 4 on day -5 to day -2 when combined with busulfan (FluBu), or at 30 mg/m2 IV x 4 on day -5 to day -2 when combined with melphalan (FluMel).", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Busulfan will be administered at 3.2 mg/kg/day IV x 2 on day -5 to day -4 (FluBu2), or at 3.2 mg/kg/day IV x 4 on day -5 to day -2 (FluBu4).", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Melphalan will be administered at 140 mg/m2 IV x 1 on day -1 (FluMel 140) or at 180 mg/m2 IV x 1 on day -1 (FluMel 180).", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Methotrexate will be administered at 5 mg/m2 IV per day on day +1, +3, +6 and +11 as standard graft-versus-host disease prophylaxis.", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Carfilzomib", 
                "description": "Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Melphalan", 
                "Methotrexate", 
                "Fludarabine monophosphate", 
                "Tacrolimus", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Allogeneic Transplantation", 
            "Carfilzomib", 
            "Relapse", 
            "Graft-Versus-Host Disease", 
            "Multiple Myeloma", 
            "Lymphoma", 
            "Leukemia"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "pawarode@umich.edu", 
                "last_name": "Attaphol Pawarode, M.D.", 
                "phone": "734-936-8785"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "investigator": {
                "last_name": "Attaphol Pawarode, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies", 
        "overall_contact": {
            "email": "pawarode@umich.edu", 
            "last_name": "Attaphol Pawarode, M.D.", 
            "phone": "734-936-8785"
        }, 
        "overall_official": {
            "affiliation": "University of Michgan Cancer Center", 
            "last_name": "Attaphol Pawarode, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients who are alive and have not developed relapse/progression of primary disease or clinical grade III-IV acute graft-versus-host disease (GVHD) or chronic GVHD requiring systemic treatment.", 
            "measure": "The proportion of patients who are alive and have not developed any \"event\"", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145403"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Attaphol Pawarode, M.D.", 
            "investigator_title": "Clinical Assistant Professor of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from day 0 to the date of the first Progression/ Relapse.", 
                "measure": "Progression/ Relapse-free survival time", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The time from day 0 to the day of death from any cause.", 
                "measure": "Overall survival time", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The type and number of adverse events related to the study drug.", 
                "measure": "Number of regimen related toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days post treatment"
            }, 
            {
                "description": "The cumulative incidence of acute Graft Versus Host Disease (GVHD)", 
                "measure": "Cumulative incidence of acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The cumulative incidence of chronic Graft Versus Host Disease (GVHD)", 
                "measure": "Cumulative incidence of chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The cumulative incidence of non-relapse mortality", 
                "measure": "Cumulative incidence of non-relapse mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}